Cargando…

Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV)

INTRODUCTION: The Canadian Sentinel Practitioner Surveillance Network reports vaccine effectiveness (VE) for the 2018/19 influenza A(H3N2) epidemic. AIM: To explain a paradoxical signal of increased clade 3C.3a risk among 35–54-year-old vaccinees, we hypothesise childhood immunological imprinting an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skowronski, Danuta M, Sabaiduc, Suzana, Leir, Siobhan, Rose, Caren, Zou, Macy, Murti, Michelle, Dickinson, James A, Olsha, Romy, Gubbay, Jonathan B, Croxen, Matthew A, Charest, Hugues, Bastien, Nathalie, Li, Yan, Jassem, Agatha, Krajden, Mel, De Serres, Gaston
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Centre for Disease Prevention and Control (ECDC) 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864978/ https://www.ncbi.nlm.nih.gov/pubmed/31771709 http://dx.doi.org/10.2807/1560-7917.ES.2019.24.46.1900585

Ejemplares similares

Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020
por: Skowronski, Danuta M, et al.
Publicado: (2020)

Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019
por: Skowronski, Danuta M, et al.
Publicado: (2019)

Influenza Vaccine Effectiveness by A(H3N2) Phylogenetic Subcluster and Prior Vaccination History: 2016–2017 and 2017–2018 Epidemics in Canada
por: Skowronski, Danuta M, et al.
Publicado: (2020)

Children under 10 years of age were more affected by the 2018/19 influenza A(H1N1)pdm09 epidemic in Canada: ‎possible cohort effect following the 2009 influenza pandemic
por: Skowronski, Danuta M, et al.
Publicado: (2019)

Influenza Vaccine Does Not Increase the Risk of Coronavirus or Other Noninfluenza Respiratory Viruses: Retrospective Analysis From Canada, 2010–2011 to 2016–2017
por: Skowronski, Danuta M, et al.
Publicado: (2020)

Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23
por: Skowronski, Danuta M, et al.
Publicado: (2023)

Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada
por: Kim, Shinhye, et al.
Publicado: (2022)

Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017
por: Skowronski, Danuta M, et al.
Publicado: (2017)

Vaccine Effectiveness Against Lineage-matched and -mismatched Influenza B Viruses Across 8 Seasons in Canada, 2010–2011 to 2017–2018
por: Skowronski, Danuta M, et al.
Publicado: (2019)

Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015–2016 Season in Canada
por: Skowronski, Danuta M, et al.
Publicado: (2017)

Should Sex Be Considered an Effect Modifier in the Evaluation of Influenza Vaccine Effectiveness?
por: Chambers, Catharine, et al.
Publicado: (2018)

A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014–2015 Season
por: Skowronski, Danuta M., et al.
Publicado: (2016)

Low 2012–13 Influenza Vaccine Effectiveness Associated with Mutation in the Egg-Adapted H3N2 Vaccine Strain Not Antigenic Drift in Circulating Viruses
por: Skowronski, Danuta M., et al.
Publicado: (2014)

Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018
por: Skowronski, Danuta M, et al.
Publicado: (2018)

Age-Related Differences in Influenza B Infection by Lineage in a Community-Based Sentinel System, 2010–2011 to 2015–2016, Canada
por: Skowronski, Danuta M, et al.
Publicado: (2017)

Influenza Classification Suite: An automated Galaxy workflow for rapid influenza sequence analysis
por: Eisler, Diane, et al.
Publicado: (2020)

SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada
por: El Adam, Shiraz, et al.
Publicado: (2022)

Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada
por: Skowronski, Danuta M., et al.
Publicado: (2022)

Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada
por: Skowronski, Danuta M, et al.
Publicado: (2021)

Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009
por: Skowronski, Danuta M, et al.
Publicado: (2011)

Rev. Mr. Hill, on Vaccination
por: Hill, Rowland
Publicado: (1807)

The Rev. Mr. Jenner, on Vaccine
por: Jenner, G. C.
Publicado: (1801)

Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada
por: Skowronski, Danuta M, et al.
Publicado: (2022)

Influenza Vaccination of Healthcare Workers: Critical Analysis of the Evidence for Patient Benefit Underpinning Policies of Enforcement
por: De Serres, Gaston, et al.
Publicado: (2017)

Vaccine Effectiveness Against Laboratory-Confirmed Influenza Hospitalizations Among Elderly Adults During the 2010–2011 Season
por: Kwong, Jeffrey C., et al.
Publicado: (2013)

The Rev. Mr. Finch, on Vaccine Inoculation
por: Finch, W.
Publicado: (1800)

Rev. Mr. Rowland Hill, on Vaccination
por: Hill, Rowland
Publicado: (1807)

Ecological Fallacy, Nonspecific Outcomes, and the Attribution of Disproportionate Vaccine Benefits
por: De Serres, Gaston, et al.
Publicado: (2018)

Increase in Hospital Admissions for Severe Influenza A/B among Travelers on Cruise Ships to Alaska, 2015
por: Payne, Michael, et al.
Publicado: (2018)

Age-Associated Seroprevalence of Coronavirus Antibodies: Population-Based Serosurveys in 2013 and 2020, British Columbia, Canada
por: Tanunliong, Guadalein, et al.
Publicado: (2022)

Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada
por: Skowronski, Danuta M, et al.
Publicado: (2022)

Mid-Season Estimates of Influenza Vaccine Effectiveness against Influenza A(H3N2) Hospitalization in the Elderly in Quebec, Canada, January 2015
por: Gilca, Rodica, et al.
Publicado: (2015)

Uptake of SARS-CoV-2 vaccination among structurally-marginalized people who use drugs in Vancouver, Canada
por: Reddon, Hudson, et al.
Publicado: (2023)

Temporal changes in respiratory adenovirus serotypes circulating in the greater Toronto area, Ontario, during December 2008 to April 2010
por: Abbas, Kaniza Zahra, et al.
Publicado: (2013)

Role of Egg-adaptation Mutations in Low Influenza A(H3N2) Vaccine Effectiveness During the 2012–2013 Season
por: Skowronski, Danuta M, et al.
Publicado: (2018)

Evidence in a Cluster Randomized Controlled Trial of Increased 2009 Pandemic Risk Associated With 2008–2009 Seasonal Influenza Vaccine Receipt
por: Skowronski, Danuta M, et al.
Publicado: (2019)

False-positivity in diagnosis of brucellosis associated with Rev-1 vaccine
por: Gunes, Hayati, et al.
Publicado: (2013)

Randomized Controlled Ferret Study to Assess the Direct Impact of 2008–09 Trivalent Inactivated Influenza Vaccine on A(H1N1)pdm09 Disease Risk
por: Skowronski, Danuta M., et al.
Publicado: (2014)

Caution Required in the Use of Administrative Data and General Laboratory Submissions for Influenza Vaccine Effectiveness Estimation
por: Skowronski, Danuta M, et al.
Publicado: (2019)

Acute Respiratory Infections in Travelers Returning from MERS-CoV–Affected Areas
por: German, Matthew, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_605rs0u8aml5nnjgosguidavuf